Related Experiment Videos
Polymyalgia rheumatica and corticosteroids: how much for how long?
Annals of the Rheumatic Diseases
|August 1, 1983
Summary
Corticosteroid treatment effectively manages polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) with minimal complications. While withdrawal is possible, relapses can occur, indicating personalized treatment approaches are essential for these inflammatory conditions.
Area of Science:
- Rheumatology
- Internal Medicine
- Clinical Pharmacology
Background:
- Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are inflammatory conditions requiring long-term management.
- Corticosteroids are the mainstay treatment, but optimal dosing and duration remain critical considerations.
Purpose of the Study:
- To evaluate the efficacy and safety of corticosteroid treatment in patients with PMR or GCA.
- To determine the long-term outcomes, including relapse rates, after corticosteroid withdrawal.
Main Methods:
- Prospective study of 176 patients diagnosed with PMR or GCA between 1968 and 1980.
- Initial corticosteroid doses adjusted based on diagnosis (10 mg prednisolone for PMR, 20 mg for GCA).
- Regular follow-up to ascertain minimum effective doses and monitor for complications.
Main Results:
- Initial low-dose corticosteroid regimens were adequate for symptom control in most patients.
- Serious disease complications were avoided with regular follow-up and dose optimization.
- Of 72 patients who withdrew corticosteroids after a mean of 31 months, 30 relapsed within 21 months.
- No clinical factors predicted relapse risk.
Conclusions:
- Corticosteroid therapy is effective and generally safe for PMR and GCA when managed with regular follow-up.
- Relapses are common after treatment withdrawal, and no specific predictors were identified.
- Individualized treatment strategies, rather than rigid protocols, are recommended for managing PMR and GCA.